Single infusion of Reclast increases bone mass for two years in postmenopausal women with osteopenia, a condition that can lead to osteoporosis[1] Approximately 22 million women in US have osteopenia, ...

Reclast (zoledronic acid or zoledronate) is approved by the Food and Drug Administration (FDA) to treat and prevent osteoporosis in males, females after menopause, and people taking glucocorticoids.

EAST HANOVER, N.J., June 5 /PRNewswire/ -- The US Food and Drug Administration (FDA) has broadened the US indication for once-yearly Reclast(R) (zoledronic acid) Injection to include the prevention of ...

June 4, 2009 — The FDA this month has approved zoledronic acid infusion (Reclast, Novartis Pharmaceuticals Corp) for the prevention of postmenopausal osteoporosis during a 2-year period. "It is very ...

Reclast (zoledronic acid) is a medication that the Food and Drug Administration (FDA) has approved for preventing and treating osteoporosis in females after menopause, males, and individuals who take ...

The U.S. Food and Drug Administration (FDA) has approved Reclast® (zoledronic acid) Injection, the first and only once-yearly treatment for postmenopausal osteoporosis. Approximately 8 million women ...

BOSTON (Reuters) - The Novartis osteoporosis drug Reclast, given once a year, reduces the risk of broken bones for three years but may spark an abnormal heart rhythm in some patients, researchers said ...

BOSTON (MarketWatch) -- Novartis AG said early Monday that its bone medication Reclast has also been approved by the Food and Drug Administration to treat postmenopausal osteoporosis. The drug, ...

Drug is a once-yearly IV injection for women with postmenopausal osteoporosis. FDA sanctioned Novartis’ Reclast for the treatment of postmenopausal osteoporosis. Unlike oral bisphosphonate therapies ...

An experimental treatment for bone-thinning osteoporosis appears to prevent spine and hip fractures even though it is given only once a year, eliminating the need for a strict daily pill regimen, ...